- 米国企業
- CRISPR Therapeutics AG
CRISPR Therapeutics AGCRSP
時価総額
$44.7億
PER
| 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| Collaboration Revenue | - | - | - | - | 1 | 913 | 0 |
| Grant | - | - | - | - | 0 | 2 | 1 |
| Total revenue | 5 | 41 | 3 | 290 | 1 | 915 | 1 |
| Research and development | 42 | 70 | 114 | 179 | 267 | 439 | 462 |
| General and administrative | 31 | 36 | 48 | 63 | 88 | 103 | 102 |
| Collaboration Expense | - | - | - | - | - | - | 110 |
| Total operating expenses | 73 | 106 | 162 | 243 | 355 | 541 | 674 |
| (Loss) income from operations | -68 | -65 | -159 | 47 | -354 | 374 | -673 |
| Other income, net | 79 | -0 | -1 | 26 | 6 | 6 | 23 |
| Total other income, net | 45 | -2 | -5 | 21 | 6 | 6 | 23 |
| Net income (loss) before income taxes | -23 | -67 | -164 | 67 | -348 | 380 | -650 |
| Benefit (provision) for income taxes | 0 | 2 | 1 | 0 | 1 | 2 | -0 |
| Net (loss) income | -23 | -68 | -165 | 67 | -349 | 378 | -650 |
| Foreign currency translation adjustment | -0 | 0 | -0 | 0 | 0 | -0 | -0 |
| Unrealized loss on marketable securities | - | - | - | - | -0 | -5 | -10 |
| Comprehensive (loss) income | -23 | -68 | -165 | 67 | -349 | 373 | -661 |
| Earnings Per Share, Basic | - | - | - | 1.23 | -5.29 | 4.97 | -8.36 |
| Earnings Per Share, Diluted | - | - | - | 1.17 | -5.29 | 4.7 | -8.36 |